Viewing Study NCT06333132


Ignite Creation Date: 2025-12-24 @ 9:57 PM
Ignite Modification Date: 2025-12-25 @ 7:35 PM
Study NCT ID: NCT06333132
Status: NOT_YET_RECRUITING
Last Update Posted: 2024-03-27
First Post: 2024-03-13
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Deciphering the Role of Incretin Hormones in Weight Loss-induced Remission of Type 2 Diabetes (DIABeat)
Sponsor: Azienda Ospedaliero, Universitaria Pisana
Organization:

Study Overview

Official Title: Deciphering the Role of Incretin Hormones in Weight Loss-induced Remission of Type 2 Diabetes
Status: NOT_YET_RECRUITING
Status Verified Date: 2024-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: DiabEATit
Brief Summary: The goal of this mechanistic study is to investigate the role of incretin hormones on weight loss-induced type 2 diabetes remission.
Detailed Description: Participants will undergo an intensive, individualized dietary treatment to achieve a 10% reduction in body weight, during which glucose-lowering therapy will be withdrawn. Before and after the intervention, the patients will undergo:

* measurement of fasting glucose and glycated hemoglobin
* Indirect calorimetry
* oral glucose tolerance test
* intravenous glucose tolerance test
* quality of life and diet-related questionnaires
* 72-hour food records

At the end of the protocol, subjects will be followed up to maintain lifestyle changes and intercept cases of diabetes relapse.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: